- Home
- PRAX vs VRNS Comparison
PRAX vs VRNS Comparison
Compare PRAX & VRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRAX | VRNS |
|---|---|---|
| Founded | 2015 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 3.9B |
| IPO Year | 2020 | 2014 |
Fundamental Metrics
Financial Performance| Metric | PRAX | VRNS |
|---|---|---|
| Price | $286.98 | $32.12 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 20 |
| Target Price | ★ $373.79 | $59.65 |
| AVG Volume (30 Days) | 771.9K | ★ 2.2M |
| Earning Date | 11-05-2025 | 02-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $7,463,000.00 | ★ $608,677,000.00 |
| Revenue This Year | N/A | $14.57 |
| Revenue Next Year | $12,467.71 | $15.80 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 364.98 | 11.37 |
| 52 Week Low | $26.70 | $30.02 |
| 52 Week High | $317.72 | $63.90 |
Technical Indicators
Market Signals| Indicator | PRAX | VRNS |
|---|---|---|
| Relative Strength Index (RSI) | 63.90 | 38.67 |
| Support Level | $285.95 | $32.63 |
| Resistance Level | $317.72 | $33.68 |
| Average True Range (ATR) | 12.78 | 1.03 |
| MACD | -1.09 | 0.33 |
| Stochastic Oscillator | 43.76 | 23.80 |
Price Performance
Historical ComparisonAbout PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
About VRNS Varonis Systems Inc.
Varonis Systems is a cybersecurity vendor focused on data privacy and security. The firm is currently undergoing a cloud transition as it weans its on-premises customers over to its cloud products that are delivered as software-as-a-service. The New York-based firm was founded in 2005 and went public in 2014.